Video Upload Options

References

1. Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF,Silvestri G, Skerka C, Józsi M, Zipfel PF, Hageman GS, Smith RJ. Variations inthe complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) areassociated with membranoproliferative glomerulonephritis type II (dense depositdisease). J Med Genet. 2006 Jul;43(7):582-9.
2. Atkinson JP, Goodship TH. Complement factor H and the hemolytic uremicsyndrome. J Exp Med. 2007 Jun 11;204(6):1245-8.
3. Boon CJ, Klevering BJ, Hoyng CB, Zonneveld-Vrieling MN, Nabuurs SB, BloklandE, Cremers FP, den Hollander AI. Basal laminar drusen caused by compoundheterozygous variants in the CFH gene. Am J Hum Genet. 2008 Feb;82(2):516-23.doi: 10.1016/j.ajhg.2007.11.007.
4. Boon CJ, van de Kar NC, Klevering BJ, Keunen JE, Cremers FP, Klaver CC, Hoyng CB, Daha MR, den Hollander AI. The spectrum of phenotypes caused by variants inthe CFH gene. Mol Immunol. 2009 May;46(8-9):1573-94. doi:10.1016/j.molimm.2009.02.013.
5. Despriet DD, Klaver CC, Witteman JC, Bergen AA, Kardys I, de Maat MP,Boekhoorn SS, Vingerling JR, Hofman A, Oostra BA, Uitterlinden AG, Stijnen T, vanDuijn CM, de Jong PT. Complement factor H polymorphism, complement activators,and risk of age-related macular degeneration. JAMA. 2006 Jul 19;296(3):301-9.
6. Donoso LA, Vrabec T, Kuivaniemi H. The role of complement Factor H inage-related macular degeneration: a review. Surv Ophthalmol. 2010May-Jun;55(3):227-46. doi: 10.1016/j.survophthal.2009.11.001. Review.
7. Francis PJ, Schultz DW, Hamon S, Ott J, Weleber RG, Klein ML. Haplotypes inthe complement factor H (CFH) gene: associations with drusen and advancedage-related macular degeneration. PLoS One. 2007 Nov 28;2(11):e1197.
8. Li M, Atmaca-Sonmez P, Othman M, Branham KE, Khanna R, Wade MS, Li Y, Liang L,Zareparsi S, Swaroop A, Abecasis GR. CFH haplotypes without the Y402H codingvariant show strong association with susceptibility to age-related maculardegeneration. Nat Genet. 2006 Sep;38(9):1049-54.
9. Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA,Macher MA, Zuber J, Karras A, Provot F, Moulin B, Grünfeld JP, Niaudet P, LesavreP, Frémeaux-Bacchi V. Acquired and genetic complement abnormalities play acritical role in dense deposit disease and other C3 glomerulopathies. Kidney Int.2012 Aug;82(4):454-64. doi: 10.1038/ki.2012.63.
10. Xiao X, Pickering MC, Smith RJ. C3 glomerulopathy: the genetic and clinicalfindings in dense deposit disease and C3 glomerulonephritis. Semin Thromb Hemost.2014 Jun;40(4):465-71. doi: 10.1055/s-0034-1376334.
11. Zipfel PF, Skerka C, Chen Q, Wiech T, Goodship T, Johnson S, Fremeaux-BacchiV, Nester C, de Córdoba SR, Noris M, Pickering M, Smith R. The role of complementin C3 glomerulopathy. Mol Immunol. 2015 Sep;67(1):21-30. doi:10.1016/j.molimm.2015.03.012.